Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBI-04711 is a first-generation botanical extract developed by Phoenix Biotechnology, Inc. Derived from the oleander plant (*Nerium oleander*), it is uniquely processed to be free of cardiac glycosides, specifically excluding oleandrin to mitigate potential cardiotoxicity. The extract contains a concentrated mixture of oleander-derived triterpenes and is being investigated for its neuroprotective properties. Preclinical research suggests potential utility in treating neurodegenerative conditions by leveraging the bioactivity of triterpenoids without the narrow therapeutic index associated with traditional oleander extracts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PBI-04711.